Mass Tort News8 min readGLP-1 Vision Loss MDL Grows 70% Ahead of September HearingsThe GLP-1 NAION vision-loss MDL hit 146 cases on the July JPML report — up 70% in two months — as the GI-injury MDL heads to Rule 702 hearings September 10-18.mass tortGLP-1Ozempic+4Jul 10, 2026Read
Mass Tort News6 min readNew GLP-1 Pill Approved as Ozempic MDL Nears TrialFDA approves Eli Lilly's Foundayo — the first oral GLP-1 with no fasting requirement — as 3,363 pending GLP-1 lawsuits approach critical deadlines.mass tortGLP-1Ozempic+2Apr 7, 2026Read
Legal Updates7 min readFDA Warns Novo Nordisk on Unreported DeathsFDA cites 'systemic failures' in Novo Nordisk's adverse event reporting for Ozempic and Wegovy, including unreported patient deaths.OzempicFDAmass tort+2Mar 24, 2026Read
Mass Tort News6 min read4,400 GLP-1 Lawsuits Filed: What Firms Need to KnowGLP-1 drug lawsuits surged 130% in 2025, with 75% alleging gastroparesis. Bellwether trials expected mid-2026.mass tortGLP-1Ozempic+2Feb 3, 2026Read
Mass Tort News10 min readOzempic Litigation Comprehensive Guide: August 2025 Updates and Medical Record ChallengesComplete guide to Ozempic litigation including Judge Marston's landmark ruling, NAION vision loss claims, and how law firms are managing the medical record challenges with 2,190+ cases in MDL 3094.Ozempicmass tortsgastroparesis+4Sep 22, 2025Read